Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. j. med. biol. res ; 48(11): 1004-1009, Nov. 2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-762903

RESUMO

Sex hormones from environmental and physiological sources might play a major role in the pathogenesis of hepatoblastoma in children. This study investigated the effects of estradiol and bisphenol A on the proliferation and telomerase activity of human hepatoblastoma HepG2 cells. The cells were divided into 6 treatment groups: control, bisphenol A, estradiol, anti-estrogen ICI 182,780 (hereinafter ICI), bisphenol A+ICI, and estradiol+ICI. Cell proliferation was measured based on average absorbance using the Cell Counting-8 assay. The cell cycle distribution and apoptotic index were determined by flow cytometry. Telomerase activity was detected by polymerase chain reaction and a telomeric repeat amplification protocol assay. A higher cell density was observed in bisphenol A (P<0.01) and estradiol (P<0.05) groups compared with the control group. Cell numbers in S and G2/M phases after treatment for 48 h were higher (P<0.05), while the apoptotic index was lower (P<0.05) and telomerase activities at 48 and 72 h (P<0.05) were higher in these groups than in the control group. The cell density was also higher in bisphenol A+ICI (P<0.01) and estradiol+ICI (P<0.05) groups compared with the ICI group. Furthermore, cell numbers were increased in S and G2/M phases (P<0.05), while the apoptotic index was lower (P<0.05) and telomerase activities at 48 and 72 h were higher (P<0.05) in these groups than in the ICI group. Therefore, bisphenol A and estradiol promote HepG2 cell proliferation in vitro by inhibition of apoptosis and stimulation of telomerase activity via an estrogen receptor-dependent pathway.


Assuntos
Humanos , Compostos Benzidrílicos/farmacologia , Proliferação de Células/efeitos dos fármacos , Estradiol/farmacologia , Antagonistas do Receptor de Estrogênio/farmacologia , Estrogênios não Esteroides/farmacologia , /efeitos dos fármacos , Fenóis/farmacologia , Telomerase/efeitos dos fármacos , Apoptose/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Estradiol/análogos & derivados , Citometria de Fluxo , /enzimologia , Interfase/efeitos dos fármacos , Telomerase/metabolismo
2.
Genet. mol. res. (Online) ; 2(3): 328-333, Sept. 2003.
Artigo em Inglês | LILACS | ID: lil-417597

RESUMO

Hydroxyurea is considered an antineoplastic drug, which also plays an important role in the treatment of sickle cell anemia patients. We evaluated and compared the clastogenic and cytotoxic effects of hydroxyurea, using chromosomal aberrations and mitotic index, respectively, as endpoints. In vitro short-term cultures of lymphocytes were exposed to several concentrations of this drug, at various cell cycle phases. There was a significant increase in the cytotoxicity of hydroxyurea at G1 and G1/S as well in the G2 phase of the cell cycle. Hydroxyurea did not significantly increase chromosome aberrations. There was an S-dependent cytotoxic effect of hydroxyurea, which is expected based on the known activity of hydroxyurea as an inhibitor of ribonucleotide reductase


Assuntos
Humanos , Aberrações Cromossômicas/induzido quimicamente , Antineoplásicos/toxicidade , Hidroxiureia/toxicidade , Interfase/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Análise de Variância , Determinação de Ponto Final , Fase G1/efeitos dos fármacos , Fase G1/genética , /efeitos dos fármacos , /genética , Fase S/efeitos dos fármacos , Fase S/genética , Interfase/genética , Índice Mitótico , Testes de Mutagenicidade/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA